분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2010-03-23 09:03:36 , Hit : 2848
 More support for RNAi in clinic

Posted by Edyta Zielinska
[Entry posted at 21st March 2010 06:02 PM GMT]
Comment on this news story    

Nanoparticles studded with short RNA molecules can silence target genes in melanoma patients, demonstrating the clinical feasibility of these techniques for the first time, according to research published online today (March 21) in Nature.


Nanoparticles
Image: Wikimedia/Nandiyanto
"This is a breakthrough for the field," said John Rossi from the City of Hope Cancer Center, who was not involved in the study. It's the first clinical proof that "RNA is entering the tumor cells and delivering the goods" needed to reduce the expression of target cancer-genes, he said.

While the result is clearly a boon for the fields of RNA interference (RNAi) and nanobiology, it remains to be seen whether the new therapy improves patient outcomes, scientists said.

RNAi functions by binding to the mRNA transcript of a gene before it is translated into a protein and cutting it at a specific point in the sequence, thereby reducing the amount of protein the gene can produce. Earlier trials for other diseases had injected patients with short interfering RNAs (siRNAs), resulting in improved patient health. But whether this improvement was the result of the siRNA-induced gene knockdown or a product of immune system activation due to the presence of the siRNA molecules in the bloodstream, which the body recognizes as a sign of infection, was unclear.

To get to the bottom of this question, Mark Davis from the California Institute of Technology and colleagues attached the siRNAs to nanoparticles, which effectively hide the genetic material from the immune system. The researchers also attached a ligand for a receptor that is more abundant on cancer cells to ensure that the nanoparticles were taken up predominantly by those cells. Once inside, the nanoparticles are designed to disintegrate, releasing their siRNA payload into the cells.

As part of a Phase I human clinical trial, the team looked at cancer samples of three melanoma patients injected with the siRNA-studded nanoparticles. Over several treatments, the researchers observed an increasing accumulation of the particles and a corresponding reduction in the levels of the mRNAs and proteins targeted by the siRNAs, suggesting that the siRNAs successfully interfered with gene expression in the cancer cells.

The results are "important because delivery [of the siRNAs] is the major obstacle to therapeutics," said Judy Lieberman of Harvard Medical School, who writes about RNAi in the upcoming April issue of The Scientist. "I was impressed with the degree of [mRNA] knock-down that they were able to achieve," she added.

In addition, the presence of mRNA fragments cut at the intended location indicated that the siRNA was functioning inside the cell as expected. "That's why this study is beautiful," said Sancy Leachman, a physician scientist at the University of Utah Health Sciences Center. "The mRNA is clipped in the right spot."

The study did not, however, provide an indication that the therapy was controlling the cancer, Lieberman said. "Were there fewer dividing cells, [and/or] was there any apoptosis [in the cancer cells]?," she asked. The study did not show evidence of either, and the results from the clinical study, including the results from about 12 additional patients with a variety of cancers, aren't expected for several months at least, Davis said.

Because both the receptor ligand that helps the nanoparticles traffic to cancer cells, and the gene that is targeted for knockdown by siRNA "are fairly ubiquitous" across cancer types, this therapy has the potential to work in many cancer types, said Davis. But some cancers are more or less dependent on this particular gene for survival; thus they may not be as susceptible to the genetic knock-down as others. "Ultimately we'd want a more specific targeting ligand and more specific genes," said Davis.

Still, "this is a very, very exciting finding," said Leachman. "This was a proof of principle experiment in a person," that demonstrated the feasibility of the approach.




Read more: More support for RNAi in clinic - The Scientist - Magazine of the Life Sciences http://www.the-scientist.com/blog/display/57226/#ixzz0ixAFoSfK







867   Mice Get Human Livers  이성욱 2010/02/24 4388
866   심장질환의 열쇠를 쥐고 있는 정크 DNA  이성욱 2010/02/25 4805
865   효소결핍이 C형 간염치료 관련 빈혈을 막아  이성욱 2010/02/26 4947
864   세포가 암이 되는 메커니즘 밝혀지다  이성욱 2010/02/26 5004
863   비참과 죽음 간의 유전적 연관성 발견  이성욱 2010/02/26 4806
862   버키볼에 기반한 유전자 전달  이성욱 2010/02/26 5180
861   인간의 간을 보유한 실험쥐: 간질환 치료의 새로운 연구모델  관리자 2010/02/26 4715
860   조류인플루엔자 바이러스에 날개를 달아주는 사람인플루엔자 바이러스  이성욱 2010/03/01 4850
859   암과 줄기 세포의 관계 규명!  이성욱 2010/03/02 4064
858   암과 노화와 연관되는 텔로미어를 통제하는 단백질 발견  관리자 2010/03/05 4562
857   Researchers: AIDS virus can hide in bone marrow  이성욱 2010/03/09 3189
856   Prion Disease in Mice May Help Advance Alzheimer's Research  이성욱 2010/03/09 3657
855   인체 장내 미생물의 전체 분포 밝혀지다  이성욱 2010/03/10 6025
854   HIV의 새로운 비밀 은신처 발견  이성욱 2010/03/12 4962
853   쥐를 이용한 동물 실험이 얼마나 효과가 있을까?  관리자 2010/03/15 5253
852   세포자살과 관련된 세포 “스위치” 규명!  한승렬 2010/03/19 4095
  More support for RNAi in clinic  이성욱 2010/03/23 2848
850   Nanotech robots deliver gene therapy through blood  이성욱 2010/03/23 3297
849   날아다니는 백신주사로 전환된 모기  이성욱 2010/03/24 4979
848   새로운 치료제를 이끄는 다운 증후군 연구  이성욱 2010/03/26 5986

[이전 10개] [1].. 21 [22][23][24][25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN